Compare Biogen Inc (BIIB) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Vipshop Holdings Ltd - ADR — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Vipshop Holdings Ltd - ADR trades at $15.05 (market cap $7.20B). The key difference: Biogen Inc is far larger — about 4.2× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.14% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | VIPS | |
|---|---|---|
Market Cap | $30.13B | $7.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $20.68 |
52-Week Low | $128.93 | $12.92 |
Enterprise Value | $37.20B | $3.76B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vipshop (VIPS) trades at $15.41, down 1.72% on the day, with a bullish technical signal from moving averages. The stock shows attractive valuation metrics, including a P/E of 6.79 and P/S of 0.48, while maintaining solid profitability with a net income margin of 7.07%. Recent Q1 2026 earnings met expectations, and the company is pursuing growth through an outlet store REIT strategy, as reported by Seeking Alpha on May 22, 2026.
The outlook is cautiously positive, supported by low valuations and analyst consensus, but risks include revenue stagnation and macroeconomic pressures in China. Near-term catalysts depend on Q2 2026 earnings beating the $0.62 EPS estimate to reaffirm growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
